Infectious Economics retweeted
ASHRAE approves groundbreaking Standard to safeguard indoor spaces from disease transmission. The new ASHRAE Standard 241- Control of Infectious Aerosols is a major step forward in reducing the risk of infectious disease spread in buildings. bit.ly/3pkMDAg.
#MyASHRAE
Infectious Economics retweeted
When there is limited supply of #MPOX vaccine, it's a better policy to offer a smaller dose for a larger number of people at high risk.
@CROI_Official @HIVptn @HelpEndHIV @fredhutch @InfectiousEcon
blytheadamson.com/2023/03/08…
Infectious Economics retweeted
Tell me if I need to bring COVID tests to #ISPORAnnual.
All those health economists could make fancier rapid molecular tests cost-effective. Bring lots of swabs & we can hack together batches of pools. Need PhD student to run the Value of Information analysis.
@InfectiousEcon
Infectious Economics retweeted
Rapid Covid tests — both Abbott BinaxNOW and Quidel QuickVue — aren’t catching people during their first couple days of infection, a new study shows. buff.ly/31uWbwv
Infectious Economics retweeted
Today, FDA approved the first COVID-19 vaccine for the prevention of #COVID19 disease in individuals 16 years of age and older. fda.gov/news-events/press-an…
Infectious Economics retweeted
The Broadway cast of Pass Over @passoverbway played my board game at rehearsal today!
It’s fun playing out scenarios of theater outcomes with daily PCR testing, an action plan for response to positive case, & when/where/why minimal rapid antigen testing.
#infectiouseconomics
Infectious Economics retweeted
Here is my perspective on schools this fall. Race and income inequities, both health and economic burden, are made worse with remote learning. Cost-effective, pooled, routine #COVID__19 testing can be part of the solution — focus on teachers. @USATODAY
usatoday.com/story/opinion/2…
Infectious Economics retweeted
USEFUL TOOL FOR STATES: https://teapawt.org/t.co/2FHIDyjdgZ ranks industries by contribution to local economy & #COVID19 risk. Can inform targeted testing of workers with no symptoms for early action, efficiently protecting health & economic vulnerabilities.
@MaritaZim @IDMod_org @BillGates
Infectious Economics retweeted
The next week or two we will start to turn the corner in some places in the US. This will be a triumph that we should all celebrate. But the next phase will bring new challenges. Here is my guess of how things will unfold. 1/
Infectious Economics retweeted
NEJM, what are you doing?
Now is not the time to engage in dichotomania of statistical significance.
The conclusions (no significant difference) is not compatible with the data (HR for improvement 1.24; 0.90 to 1.72)
Cc @f2harrell @ADAlthousePhD
nejm.org/doi/full/10.1056/NE…
Infectious Economics retweeted
When he was in midst of the fight against HIV/AIDS, Dr. Fauci was known to run 7 miles daily.
I just asked him if he still keeps to that exercise regimen.
No, he says, noting that he is working 19 hour days to fight the coronavirus.
He is down to 3.5 miles -- at the age of 79.
Infectious Economics retweeted
Grateful to support science-driven decision-making by Washington officials during this critical phase of the #COVID19 outbreak. Read about what generated today's graphic: https://teapawt.org/t.co/ZwrhcTc3fp @GovInslee @KCPubHealth @WADeptHealth @MayorJenny @trvrb @famulare_mike @hagedornb
Infectious Economics retweeted
We expect that generic Truvada is going to be priced at about $8,300/y. Using the methods of cost-effectiveness, we find that the fair market price of Descovy is no more than $8,670/y, far less than the current list price of $16,600/y
annals.org/aim/article-abstr… @mgh_id @MGHMedicine
Infectious Economics retweeted
A new report on the incubation period of #COVID19
annals.org/aim/fullarticle/2… @AnnalsofIM by @JustinLessler @salauer_biostat
@JohnsHopkinsSPH and colleagues
Infectious Economics retweeted
Disease modeling is informing timely interventions to control #COVID19 (#coronavirus) epidemic. But we need a systematic comparative modeling approach that bring together several models -- this will have a bigger impact. statnews.com/2020/02/14/dise… via @statnews #datascience
Infectious Economics retweeted
Replying to @cpgYALE @medrxivpreprint
These @medrxivpreprint #preprints are not yet peer reviewed. They share evidence ASAP. One report of over 1,000 pts highlights presenting symptoms (frequently fever, cough), incubation period (3 days), lab ABNL (lymphopenia common), mortality risks
https://teapawt.org/t.co/j6EyRPzjNL 2/
Infectious Economics retweeted
Here is why #preprints so important. Scientific and public health response to #2019nCoV #coronavirus requires rapid sharing of information. Fortunately, there has already been 36 #preprint manuscripts shared via @medrxivpreprint 1/5
Infectious Economics retweeted
Novel coronavirus: FDA issues Emergency Use Authorization for the first diagnostic test - This is great news that will allow for expanded testing to State Public Health laboratories. #2019nCoV @colleenkraftmd outbreaknewstoday.com/novel-…
Infectious Economics retweeted
A must read paper according to @RitaINdeFaria. @MJSculpher and Steve Palmer commenting on @NICEComms as a methods innovator rdcu.be/b0xDw
























